Cancer chemoprevention by polyphenols and their potential application as nanomedicine

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 31, Issue 1, 2013, Pages 67-98

  Tabrez, Shams ^a   Priyadarshini, Medha ^b   Urooj, Maryam ^b   Shakil, Shazi ^c   Ashraf, Ghulam Md ^a   Khan, Mohd Shahnawaz ^d   Kamal, Mohammad Amjad ^a   Alam, Qamre ^a   Jabir, Nasimudeen R ^a   Abuzenadah, Adel Mohammad ^a   Chaudhary, Adeel G A ^a   Damanhouri, Ghazi Abdullah ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b ALIGARH MUSLIM UNIVERSITY   (India)

^c INTEGRAL UNIVERSITY   (India)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

cancer; chemoprevention chemotherapy; nanomedicine; nanotechnology; polyphenols

Indexed keywords

CANCER; CANCER CHEMOPREVENTION; CANCER CHEMOTHERAPEUTIC AGENTS; CHEMOPREVENTION; MULTIDRUG RESISTANCE; PHYSIOLOGICAL SYSTEMS; POLYPHENOLS; SCIENTIFIC LITERATURE;

CELL DEATH; CHEMOTHERAPY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; NANOTECHNOLOGY; NUTRIENTS;

DISEASES;

AGLYCONE; ANTIOXIDANT; APIGENIN; AVENANTHRAMIDE; BETA LAPACHONE; CAFFEIC ACID; CURCUMIN; ELLAGIC ACID; EPICATECHIN; EPICATECHIN GALLATE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FLAVONOID; GENISTEIN; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HYDROXYTYROSOL; LUTEOLIN; NANOPARTICLE; OLEUROPEIN; POLYPHENOL DERIVATIVE; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL; SOLID LIPID NANOPARTICLE; TANNIN; THEAFLAVIN; THYMOQUINONE; UNCLASSIFIED DRUG; WOGONIN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CHEMOPROPHYLAXIS; DIETARY INTAKE; DNA DAMAGE; DOWN REGULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; LIPID PEROXIDATION; MULTIDRUG RESISTANCE; NANOENCAPSULATION; NANOMEDICINE; NEOPLASM; OXIDATIVE STRESS; POLYMERIZATION; SIGNAL TRANSDUCTION; SURFACE PROPERTY; UPREGULATION; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; POLYPHENOLS;

EID: 84876141310     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590501.2013.763577     Document Type: Article

References (236)

1. Howe, H L, Wingo, P A, Thun, M J, Ries, LA, Rosenberg, HM, and, Fiegal, EG. 2001. Annual report to the nation on the status of cancer (1972-1998), featuring cancers with recent increasing trend. J Natl Cancer Inst., 93: 824-842.
2. Jemal, A, Thomas, A, Murray, T N, and, Thun, M. 2002. Cancer statistics, 2002. Cancer J Clin., 52: 23-47.
3. Aggarwal, B B, and, Shishodia, S. 2006. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol, 71: 1397-1421.
4. Jemal, A, Siegel, R, Ward, E, Murray, T, Xu, J, and, Thun, M J. 2007. Cancer statistics, 2007. Cancer J Clin., 57: 43-66.
5. Nowell, P C. 1986. Mechanisms of tumor progression. Cancer Res, 46: 2203-2207.
6. Sporn, M B, and, Suh, N. 2002. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer, 2: 537-543.
7. Sporn, M B. 1991. Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res, 51: 6215-6218.
8. Khan, N, and, Mukhtar, H. 2008. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett, 269: 269-280.
9. Wattenberg, W L. 1985. Chemoprevention of cancer. Cancer Res, 45: 1-8.
10. Khan, N, and, Mukhtar, H. 2010. Cancer chemoprevention. Comprehensive Toxicol., 14: 417-431.
11. Bode, A M, and, Dong, Z. 2004. Targeting signal transduction pathways by chemopreventive agents. Mutat Res., 555: 33-51.
12. Stevenson, D E, and, Hurst, R D. 2007. Polyphenolic phytochemicals-just antioxidants or much more?. Cell Mol Life Sci, 64: 2900-2916.
13. Di Domenico, F, Foppoli, C, Coccia, R, and, Perluigi, M. 2011. Antioxidants in cervical cancer: chemopreventive and chemotherapeutic effects of polyphenols. Biochim Biophys Acta,. doi:10.1016/j.bbadis.2011.10.005
14. Shukla, S, and, Gupta, S. 2010. " Apigenin and cancer chemoprevention ". In Bioactive foods in promoting health: fruit and vegetables Edited by: Watson, R R and Pree, V R. 663-689. Elsevier: Netherlands
15. Khan, N, and, Mukhtar, H. 2010. Cancer and metastasis: prevention and treatment by green tea. Cancer Metastasis Rev, 29: 435-445.
16. Fresco, P, Borges, F, Diniz, C, and, Marques, M P. 2006. New insights into the anticancer properties of polyphenols. Med Res Rev, 26: 747-766.
17. Duthie, S J. 2007. Berry phytochemicals, genomic stability and cancer: evidence for chemoprotection at several stages in the carcinogenic process. Mol Nutr Food Res, 51: 665-674.
18. Wahle, K WJ, Rotondo, D, Brown, I, and, Heys, S D. 2009. " Plant phenolics in the prevention and treatment of cancer ". In Bio-farms for nutraceuticals: functional food and safety control by biosensors, Edited by: Giardi, M T, Rea, G and Berra, B. Landes Bioscience and Springer Science: New York.
19. Tyagi, S, Singh, G, Sharma, A, and, Aggarwal, G. 2010. Phytochemicals as candidate therapeutics: an overview. Int J Pharmac Sci Rev Res, 3 (1): 53-55.
20. Perron, N R, and, Brumaghim, J L. 2009. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys., 53: 75-100.
21. Hu, M-L. 2011. Dietary polyphenols as antioxidants and anticancer agents: more questions than answers. Chang Gung Med J., 34: 449-460.
22. Chen, H, Yao, K, Nadas, J, Bode, A M, Malakhova, M, Oi, N. 2012. Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods. PLoS ONE., 7 (5): e38261. doi:10.1371/journal.pone. 0038261
23. Chahar, MK, Sharma, N, Dobhal, M P, and, Joshi, Y C. 2011. Flavonoids: a versatile source of anticancer drugs. Pharmacogn Rev, 5 (9): 1-12.
24. Kanadaswami, C, Lee, L-T, Lee, P-PH, Hwang, J J, Ke, F C, Huang, Y T, and, Lee, M-T. 2005. The antitumor activities of flavonoids. In vivo, 19: 895-910.
25. Ghiringhelli, F, Rébé, C, Hichami, A, and, Delmas, D. 2012. Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. Anticancer Agents Med Chem, 12 (8): 852-873.
26. Mohan, A, Narayanan, S, Sethuraman, S, and, Krishnan, U M. 2013. Combinations of plant polyphenols and anticancer molecules: a novel treatment strategy for cancer chemotherapy. Anticancer Agents Med Chem, 13 (2): 281-295.
27. Spatafora, C, and, Tringali, C. 2012. Natural-derived polyphenols as potential anticancer agents. Anticancer Agents Med Chem, 12 (8): 902-918.
28. Bode, A M, and, Dong, Z. 2006. Molecular and cellular targets. Mol Carcinog., 45 (6): 422-430.
29. Morley, N, Clifford, T, Salter, L, Campbell, S, Gould, D, and, Curnow, A. 2005. The green tea polyphenol (-)-epigallocatechin gallate and green tea can protect human cellular DNA from ultraviolet and visible radiation-induced damage. Photodermatol Photoimmunol Photomed., 21: 15-22.
30. Umemura, T, Kai, S, Hasegawa, R, Kanki, K, Kitamura, Y, Nishikawa, A. 2003. Prevention of dual promoting effects of pentachlorophenol, an environmental pollutant, on diethylnitrosamineinduced hepato- and cholangiocarcinogenesis in mice by green tea infusion. Carcinogenesis., 24: 1105-1109.
31. Ioannides, C, and, Yoxall, V. 2003. Antimutagenic activity of tea: role of polyphenols. Curr Opin Clin Nutr Metab Care, 6 (6): 649-656.
32. Yamagishi, M, Natsume, M, Nagaki, A, Adachi, T, Osakabe, N, Takizawa, T, Kumon, H, and, Osawa, T. 2000. Antimutagenic activity of cacao: inhibitory effect of cacao liquor polyphenols on the mutagenic action of heterocyclic amines. J Agric Food Chem, 48 (10): 5074-5078.
33. Santhosh, KT, Swarnam, J, and, Ramadasan, K. 2005. Potent suppressive effect of green tea polyphenols on tobacco-induced mutagenicity. Phytomedicine, 12 (3): 216-220.
34. Krishnan, R, and, Maru, G B. 2005. Inhibitory effect(s) of polymeric black tea polyphenols on the formation of B(a)P-derived DNA adducts in mouse skin. J Environ Pathol Toxicol Oncol, 24 (2): 79-90.
35. Moon, YJ, Wang, X, and, Morris, M E. 2006. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro, 20 (2): 187-210.
36. Johnson, M K, and, Loo, G. 2000. Effects of epigallocatechin gallate and quercetin on oxidative damage to cellular DNA. Mutat Res., 459: 211-218.
37. Heijnen, C G, Haenen, G R, van Acker, F A, van der Vijgh, W J, and, Bast, A. 2001. Flavonoids as peroxynitrite scavengers: the role of the hydroxyl groups. Toxicol In Vitro., 15: 3-6.
38. Rajendran, P, Ekambaram, G, and, Sakthisekaran, D. 2008. Cytoprotective effect of mangiferin on benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Basic Clin Pharmacol Toxicol., 103: 137-142.
39. Lee, D E, Shin, B J, Hur, H J, Kim, J H, Kim, J, Kang, N J. 2010. Quercetin, the active phenolic component in kiwifruit, prevents hydrogen peroxide-induced inhibition of gap-junction intercellular communication. Br J Nutr., 104: 164-170.
40. Fresco, P, Borges, F, Diniz, C, and, Marques, M P. 2006. New insights into the anticancer properties of polyphenols. Med Res Rev, 26: 747-766.
41. Le Corre, L, Chalabi, N, Delort, L, Bignon, Y-J, and, Bernard-Gallon, DJ. 2005. Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res, 49: 462-471.
42. Plaumann, B, Fritsche, M, Rimpler, H, Brandner, G, and, Hess, R D. 1996. Flavonoids activate wild-type p53. Oncogene, 13: 1605-1614.
43. Ren, W, Qiao, Z, Wang, H, Zhu, L, and, Zhang, L. 2003. Flavonoids: promising anticancer agents. Med Res Rev., 23 (4): 519-534.
44. Gerritsen, M E. 1998. Flavonoids: inhibitors of cytokine induced gene expression. Adv Exp Med Biol., 439: 183-190.
45. Amado, N G, Fonseca, B F, Cerqueira, D M, Neto, V M, and, Abreu, J G. 2011. Flavonoids: potential Wnt/beta-catenin signaling modulators in cancer. Life Sci, 89: 545-554.
46. Chen, C, Zhou, J, and, Ji, C. 2010. Quercetin: a potential drug to reverse multidrug resistance. Life Sci., 87 (11-12): 333-338.
47. Lugli, E, Ferraresi, R, Roat, E, Troiano, L, Pinti, M, Nasi, M. 2009. Quercetin inhibits lymphocyte activation and proliferation without inducing apoptosis in peripheral mononuclear cells. Leukem Res., 33 (1): 140-150.
48. Amado, N G, Cerqueira, D M, Menezes, F S, da Silva, J F, Neto, V M, and, Abreu, J G. 2009. Isoquercitrin isolated from Hyptis fasciculata reduces glioblastoma cell proliferation and changes β-catenin cellular localization. Anticancer Drugs, 20 (7): 543-552.
49. Russo, M, Nigro, P, Rosiello, R, DArienzo, R, and, Russo, G L. 2007. Quercetin enhances CD95- and TRAIL-induced apoptosis in leukemia cell lines. Leukemia., 21 (5): 130-1133.
50. Kalra, N, Seth, K, Prasad, S, Singh, M, Pant, A B, and, Shukla, Y. 2007. Theaflavins induced apoptosis of LNCaP cells is mediated through induction of p53, down-regulation of NF-kappa B and mitogen-activated protein kinases pathways. Life Sci., 80 (23): 2137-2146.
51. Gates, M A, Vitonis, A F, Tworoger, S S, Rosner, B, Titus-Ernstoff, L, Hankinson, S E. 2009. Flavonoid intake and ovarian cancer risk in a population-based case-control study. Int J Cancer., 124 (8): 1918-1925.
52. Cappelletti, V, Miodini, P, Di Fronzo, G, and, Daidone, M G. 2006. Modulation of estrogen receptor-β isoforms by phytoestrogens in breast cancer cells. Int J Oncol., 28 (5): 1185-1191.
53. Mukherjee, S, Acharya, B R, Bhattacharyya, B, and, Chakrabarti, G. 2010. Genistein arrests cell cycle progression of A549 cells at the G(2)/M phase and depolymerizes interphase microtubules through binding to a unique site of tubulin. Biochemistry., 49 (8): 1702-1712.
54. Kim, H, Lee, M J, Kim, J E, Park, S D, Moon, H I, and, Park, W H. 2010. Genistein suppresses tumor necrosis factor-alpha-induced proliferation via the apoptotic signaling pathway in human aortic smooth muscle cells. J Agric Food Chem., 58 (3): 2015-2019.
55. Kim, H, Park, J S, Seo, M S, Jung, J W, Lee, Y S, and, Kang, K S. 2010. Genistein and daidzein repress adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells via Wnt/β-catenin signalling or lipolysis. Cell Prolif., 43 (6): 594-605.
56. Pavese, J M, Farmer, R L, and, Bergan, R C. 2010. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev., 29 (3): 465-482.
57. Halliwell, B. 2008. Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies?. Arch Biochem Biophys, 476 (2): 107-112.
58. Gupta, S, Afaq, F, and, Mukhtar, H. 2001. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophy Res Comm, 287: 914-920.
59. Wei, H, Tye, L, Bresnick, E, and, Birt, D F. 1990. Inhibitory effect of apigenin, a plant flavonoid, on epi- dermal ornithine decarboxylase and skin tumor promotion in mice. Cancer Res, 50: 499-502.
60. Van, D R, Xue, Y, Knudson, A, and, Pelling, J C. 2003. The chemopreventive bioflavonoid apigenin modulates signal transduction pathways in keratinocyte and colon carcinoma cell lines. J Nutr, 133: 3800S-3804S.
61. Wang, I K, Lin-Shiau, S Y, and, Lin, J K. 1999. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer, 35: 1517-1525.
62. Iwashita, K, Kobori, M, Yamaki, K, and, Tsushida, T. 2000. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci Biotech Biochem, 64: 1813-1820.
63. Shukla, S, and, Gupta, S. 2007. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle, 6: 1102-1114.
64. Lepley, D M, and, Pelling, J C. 1997. Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. Mol Carcinogen., 19: 74-82.
65. Elangovan, V, Sekar, N, and, Govindasamy, S. 1994. Chemopreventive potential of dietary bioflavonoids against 20-methylcholanthreneinduced tumorigenesis. Cancer Lett, 87: 107-113.
66. Manju, V, and, Nalini, N. 2005. Chemopreventive potential of luteolin during colon carcinogenesis induced by 1,2-dimethylhydrazine. Ital J Biochem, 54: 268-275.
67. Manju, V, and, Nalini, N. 2007. Protective role of luteolin in 1,2- dimethylhydrazine induced experimental colon carcinogenesis. Cell Biochem Funct, 25: 189-194.
68. López-Lázaro, M. 2009. Distribution and biological activities of the flavonoid luteolin. Mini-Rev Med Chem, 9: 31-59.
69. Colomer, R, and, Menendez, J A. 2006. Mediterranean diet, olive oil and cancer. Clin Transl Oncol, 8: 15-21.
70. Wahle, K WJ, Caruso, D, Ochoa, J, and, Quiles, JL. 2004. Olive oil and modulation of cell signaling in disease prevention. Lipids, 39: 1223-1231.
71. Way, T D, Kao, M C, and, Lin, J K. 2004. Apigenein induces apoptosis through proteosomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphoinositol 3-kinase/Akt-dependent pathway. J Biol Chem, 279 (6): 4479-4489.
72. Chung, T W, Moon, S K, Chang, Y C, Ko, J H, Lee, Y C, Cho, G, Kim, S H, Kim, G J, and, Kim, C H. 2004. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism. FASEB J., 14: 1670-1681.
73. Okutan, H, Ozcelikb, N, Yilmazb, H R, and, Uzb, E. 2005. Effects of caffeic acid phenethyl ester on lipid peroxidation and antioxidant enzymes in diabetic rat heart. Clin Biochem., 38: 191-196.
74. Yamada, Y, Yasui, H, and, Sakurai, H. 2006. Suppressive effect of caffeic acid and its derivatives on the generation of UVA-induced reactive oxygen species in the skin of hairless mice and pharmacokinetic analysis on organ distribution of caffeic acid in ddY mice. Photochem Photobiol., 82: 1668-1676.
75. Edderkaoui, M, Odinokova, I, Ohno, I, Gukovsky, I, Go, V L, Pandol, S J, and, Gukovskaya, A S. 2008. Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J Gastroenterol., 14: 3672-3680.
76. Hagiwara, Y, Kasukabe, T, Kaneko, Y, Niitsu, N, and, Okabe-Kado, J. 2010. Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells. Int J Hematol., 92: 136-143.
77. Mejia-Meza, E I, Yanez, J A, Remsberg, C M, Takemoto, J K, Davies, N M, Rasco, B, and, Clary, C. 2010. Effect of dehydration on raspberries: polyphenol and anthocyanin retention, antioxidant capacity, and antiadipogenic activity. J Food Sci., 75: 5-12.
78. Rogerio, A P, Fontanari, C, Borducchi, E, Keller, A C, Russo, M, Soares, E G, Albuquerque, D A, and, Faccioli, L H. 2008. Anti-inflammatory effects of Lafoensia pacari and ellagic acid in a murine model of asthma. Eur J Pharmacol., 580: 262-270.
79. Xu, Y M, Deng, J Z, Ma, J, Chen, S N, Marshall, R, Jones, S H, Johnson, R K, and, Hecht, S M. 2003. DNA damaging activity of ellagic acid derivatives. Bioorg Med Chem., 11: 1593-1596.
80. Umesalma, S, and, Sudhandiran, G. 2011. Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. Eur J Pharmacol, 660: 249-258.
81. Nandakumar, V, Singh, T, and, Katiyar, S K. 2008. Multi-targeted prevention and therapy of cancer by proanthocyanidins. Cancer Lett, 269: 378-387.
82. Sandhar, H K, Kumar, B, Prasher, S, Tiwari, P, Salhan, M, and, Sharma, P. 2011. A review of phytochemistry and pharmacology of flavonoids. Int Pharm Sci, 1 (1): 25-41.
83. Marchand, L. 2002. Cancer preventive effects of flavonoids-a review. Biomed Pharmacother, 56: 296-301.
84. Brusselmans, K, de Schrijver, E, Heyns, W, Verhoeven, G, and, Swinnen, J. 2003. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer., 106: 856-862.
85. Horie, N, Hirabayashi, N, Takahashi, Y, Miyauchi, Y, Taguchi, H, and, Takeishi, K. 2005. Synergistic effect of green tea catechins on cell growth and apoptosis induction in gastric carcinoma cells. Biol Pharm Bull., 28: 574-579.
86. Chen, C, Shen, G, Hebbar, V, Hu, R, Owuor, E, and, Kong, A. 2003. Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogen., 24: 1369-1378.
87. Wang, H, Bian, S, and, Yang, C S. 2011. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α. Carcinogen,. doi:10.1093/carcin/bgr218
88. Khan, N, Afaq, F, and, Mukhtar, H. 2007. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal., 10: 475-510.
89. Punathil, T, Tollefsbol, T O, and, Katiyar, S K. 2008. EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclise. Biochem Biophys Res Commun., 375 (1): 162-167.
90. Sah, JF, Balasubramanian, S, Eckert, RL, and, Rorke, E A. 2004. Epigallocatechin-3-gallatem inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem., 279: 12755-12762.
91. Khan, N, Afaq, F, Saleem, M, Ahmad, N, and, Mukhtar, H. 2006. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3- gallate. Cancer Res., 66: 2500-2505.
92. Surh, YJ, and, Na, H K. 2008. NF-κB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals. Genes Nutr., 2 (4): 313-317.
93. Kundu, J K, and, Suhr, Y J. 2004. Molecular basis of chemoprevention by resveratrol: NF-kB and AP-1 as potential targets. Mutat Res., 555: 65-80.
94. Singh, B N, Shankar, S, and, Srivastava, R K. 2011. Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochem Pharmacol, 82: 1807-1821.
95. Dong, Z, Ma, W, Huang, C, and, Yang, C S. 1997. Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols (-)-epigallocatechin gallate, and theaflavins. Cancer Res., 57: 4414-4419.
96. Lu, G, Liao, J, Yang, G, Reuhl, K R, Hao, X, and, Yang, C S. 2006. Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)- 1-(3-pyridyl)-1- butanone-induced lung tumorigenesis model in a/j mice by tea polyphenols and caffeine. Cancer Res., 66: 11494-11501.
97. Chung, J Y, Huang, C, Meng, X, Dong, Z, and, Yang, C S. 1999. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in h-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res., 59: 4610-4617.
98. Liang, Y C, Lin Shiau, S Y, Chen, C F, and, Lin, J K. 1999. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate. J Cell Biochem., 75: 1-12.
99. Katiyar, S K, Afaq, F, Perez, A, and, Mukhtar, H. 2001. Green tea polyphenol (-)-epigallocatechin-3-gallate treatment of human skin inhibits ultraviolet radiation-induced oxidative stress. Carcinogen., 22: 287-294.
100. Deguchi, H, Fujii, T, Nakagawa, S, Koga, T, and, Shirouzu, K. 2002. Analysis of cell growth inhibitory effects of catechin through MAPK in human breast cancer cell line T47D. Int J Oncol., 21: 1301-1305.
101. Maeda-Yamamoto, M, Suzuki, N, Sawai, Y, Miyase, T, Sano, M, Hashimoto-Ohta, A, and, Isemura, M. 2003. Association of suppression of extracellular signal-regulated kinase phosphorylation by epigallocatechin gallate with the reduction of matrix metalloproteinase activities in human fibrosarcoma HT1080 cells. J Agric Food Chem., 51: 1858-1863.
102. Kuhn, DJ, Burns, A C, Kazi, A, and, Dou, Q P. 2004. Direct inhibition of the ubiquitinproteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptor. Biochim Biophys Acta, 1682: 1-10.
103. Kim, HS, Kim, M H, Jeong, M, Hwang, Y S, Lim, S H, Shin, B A, Ahn, BW, and, Jung, Y D. 2004. EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res, 24: 747-753.
104. Manna, S, Mukherjee, S, Roy, A, Das, S, and, Panda, C K. 2009. Tea polyphenols can restrict benzo[a]pyrene-induced lung carcinogenesis by altered expression of p53-associated genes and H-ras, c-myc and cyclin D1. J Nutr Biochem, 20: 337-349.
105. Harakeh, S, Abu-El-Ardat, K, Diab-Assaf, M, Niedzwiecki, A, El-Sabban, M, and, Rath, M. 2008. Epigallocatechin-3-gallate induces apoptosis and cell cycle arrest in HTLV-1-positive and negative leukemia cells. Med Oncol, 25: 30-39.
106. Thakur, VS, Gupta, K, and, Gupta, S. 2012. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogen, 33 (2): 377-384.
107. Masuda, M, Suzui, M, and, Weinstein, I B. 2001. Effects of epigallocatechin- 3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res., 7: 4220-4229.
108. Masuda, M, Suzui, M, Lim, J T, Deguchi, A, Soh, J W, and, Weinstein, I B. 2002. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol, 2: 350-359.
109. Shimizu, M, Deguchi, A, Lim, J T, Moriwaki, H, Kopelovich, L, and, Weinstein, I B. 2005. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res, 11 (7): 2735-2746.
110. Hoffmann, J, Junker, H, Schmieder, A, Venz, S, Brandt, R, Multhoff, G, Falk, W, and, Radons, J. 2011. EGCG downregulates IL-1RI expression and suppresses IL-1-induced tumorigenic factors in human pancreatic adenocarcinoma cells. Biochem Pharmacol, 82: 1153-1162.
111. Shi, ST, Wang, Z Y, Smith, T J, Hong, J Y, Chen, W F, Ho, C T, and, Yang, C S. 1994. Effects of green leaf and black tea on 4-(methylnitrosamino)-l-(3- pyridyl)-lbutanone bioactivation, DNA methylation. and lung tumorigenesis in A/J mice. Cancer Res., 54: 4641-4647.
112. Chung, FL, Wang, M, Rivenson, A, Iatropoulos, M J, Reinhardt, J C, Pittman, B, Ho, C T, and, Amin, S G. 1998. Inhibition of lung carcinogenesis by black tea in Fischer rats treated with a tobacco-specific carcinogen: caffeine as an important constituent. Cancer Res, 58: 4096-4101.
113. Kumar, G, Dange, P, Kailaje, V, Vaidya, M M, Ramchandani, A G, and, Maru, G B. 2012. Polymeric black tea polyphenols modulate the localization and activity of 12-O-tetradecanoylphorbol-13-acetate-mediated kinases in mouse skin: mechanisms of their anti-tumor-promoting action. Free Radic Biol Med, 53 (6): 1358-1370.
114. Mujtaba, T, and, Dou, Q P. 2012. Black tea polyphenols inhibit tumor proteasome activity. In Vivo, 26 (2): 197-202.
115. Bachmeier, B, Nerlich, A G, Iancu, C M, Cilli, M, Schleicher, E, Vené, R, DellEva, R, Jochum, M, Albini, A, and, Pfeffer, U. 2007. The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem., 19: 137-152.
116. Chen, H W, Yu, S L, Chen, J J, Li, H N, Lin, Y C, Yao, P L. 2004. Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Mol Pharmacol., 65: 99-110.
117. Chen, H W, Lee, J Y, Huang, J Y, Wang, C C, Chen, W J, Su, S F. 2008. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res., 68: 7428-7438.
118. Cai, XZ, Wang, J, Li, XD, Wang, GL, Liu, FN, Cheng, MS, and, Li, F. 2009. Curcumin suppresses proliferation and invasion in human gastric cancer cells by downregulation of PAK1 activity and cyclin D1 expression. Cancer Biol Ther., 8: 1360-1368.
119. Rao, CV, Rivenson, A, Simi, B, and, Reddy, B S. 1995. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res., 55: 259-266.
120. Kawamori, T, Lubet, R, Steele, VE, Kelloff, GJ, Kaskey, RB, Rao, CV, and, Reddy, B S. 1999. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res, 59: 597-601.
121. Goel, A, and, Aggarwal, B B. 2010. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer., 62: 919-930.
122. Han, SS, Keum, YS, Seo, HJ, and, Surh, Y J. 2002. Curcumin suppresses activation of NFkappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J Biochem Mol Biol., 35: 337-342.
123. Kang, G, Kong, PJ, Yuh, YJ, Lim, SY, Yim, SV, Chun, W, and, Kim, S S. 2004. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells. J Pharmacol Sci., 94: 325-328.
124. Liu, JY, Lin, SJ, and, Lin, J K. 1993. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogen., 14: 857-861.
125. Mohan, R, Sivak, J, Ashton, P, Russo, LA, Pham, BQ, Kasahara, N, Raizman, MB, and, Fini, M E. 2000. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem., 275: 10405-10412.
126. Korutla, L, and, Kumar, R. 1994. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim Biophys Acta., 1224: 597-600.
127. Korutla, L, Cheung, JY, Mendelsohn, J, and, Kumar, R. 1995. Inhibition of ligand induced activation of epidermal growth factor receptor tyrosine phosphotylation by curcumin. Carcinogen., 16: 1741-1745.
128. Kaneuchi, M, Sasaki, M, Tanaka, Y, Yamamoto, R, Sakuragi, N, and, Dahiya, R. 2003. Resveratrol suppresses growth of Ishikawa cells through down regulation of EGF. Int J Oncol., 23: 1167-1172.
129. Prasad, CP, Rath, G, Mathur, S, Bhatnagar, D, and, Ralhan, R. 2010. Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines. Chem Biol Interact., 183: 455-461.
130. Shao, Z M, Shen, Z Z, Liu, C H, Sartippour, M R, Go, V L, Heber, D, and, Nguyen, M. 2002. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer., 98: 234-240.
131. Su, C C, Chen, G W, Lin, J G, Wu, L T, and, Chung, J G. 2006. Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor B/p65 and down-regulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res., 26: 1281-1288.
132. Leow, P C, Tian, Q, Ong, Z Y, Yang, Z, and, Ee, P L. 2010. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs., 28: 766-782.
133. Ohashi, Y, Tsuchiya, Y, Koizumi, K, Sakurai, H, and, Saiki, I. 2003. Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. Oncology., 65: 250-258.
134. Singh, M, and, Singh, N. 2011. Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells. Mol Cell Biochem., 347: 1-11.
135. Madden, K, Flowers, L, Salani, R, Horowitz, I, Logan, S, Kowalski, K, Xie, J, and, Mohammed, S I. 2009. Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer. Prostaglandins Leukot Essent Fatty Acids., 80: 9-18.
136. Maher, D M, Bell, M C, ODonnell, E A, Gupta, B K, Jaggi, M, and, Chauhan, S C. 2011. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol Carcinog, 50: 47-57.
137. Cucciolla, V, Borriello, A, Oliva, A, Galletti, P, Zappia, V, and, Della Ragione, F. 2007. Resveratrol: from basic science to the clinic. Cell Cycle., 6: 2495-2510.
138. Jang, M, Cai, L, Udeani, G O, Slowing, K V, Thomas, C F, Beecher, C W. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275: 218-220.
139. Aggarwal, B B, Bhardwaj, A, Aggarwal, R S, Seeram, N P, Shishodia, S, and, Takada, Y. 2004. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res., 24: 2783-2840.
140. Li, H, Xia, N, and, Förstermann, U. 2012. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide., 26: 102-110.
141. Leonard, S S, Xia, C, Jiang, B H, Stinefelt, B, Klandorf, H, Harris, G K, and, Shi, X. 2003. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun., 309: 1017-1026.
142. Woo, J H, Lim, J H, Kim, Y H, Suh, S I, Min, D S, Chang, J S, Lee, Y H, Park, J W, and, Kwon, T K. 2004. Resveratrol inhibits phorbol myristate acetateinduced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene., 23: 1845-1853.
143. Ulrich, S, Loitsch, S M, Rau, O, von Knethen, A, Brüne, B, Schubert-Zsilavecz, M, and, Stein, J M. 2006. Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res., 66: 7348-7354.
144. Zoberi, I, Bradbury, C M, Curry, H A, Bisht, K S, Goswami, P C, Roti Roti, J L, and, Gius, D. 2002. Radiosensitizing and anti-proliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Lett., 175: 165-173.
145. Kramer, M P, and, Wesierska-Gadek, J. 2009. Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose. Ann N Y Acad Sci., 1171: 257-263.
146. Guo, W, Nie, L, Wu, D, Wise, M L, Collins, F W, Meydani, S N, and, Meydani, M. 2010. Avenanthramides inhibit proliferation of human colon cancer cell lines in vitro. Nutr Cancer., 62 (8): 1007-1016.
147. García-Villalba, R, Carrasco-Pancorbo, A, Oliveras-Ferraros, C, Menéndez, J A, Segura-Carretero, A, and, Fernández- Gutiérrez, A. 2012. Uptake and metabolism of olive oil polyphenols in human breast cancer cells using nano-liquid chromatography coupled to electrospray ionization-time of flight-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 898: 69-77.
148. Defagó, M D, and, Soria, E A. 2010. Biomarker assessment in nutritional modulation of oxidative stress-induced cancer development by lipid-related bioactive molecules. Recent Patents on Anti-Cancer Drug Discovery, 5: 188-196.
149. Mamede, A C, Tavares, S D, Abrantes, A M, Trindade, J, Maia, J M, and, Botelho, M F. 2011. The role of vitamins in cancer: a review. Nutr Cancer, 63: 479-494.
150. Hill, M J. 1999. Mechanisms of diet and colon carcinogenesis. Eur J Cancer Prev., 8: S95-S98.
151. Borek, C. 2004. Dietary antioxidants and human cancer. Integr Cancer Ther., 3: 333-341.
152. Briviba, K, Schnäbele, K, Schwertle, E, Blockhaus, M, and, Rechkemmer, G. 2001. Beta-carotene inhibits growth of human colon carcinoma cells in vitro by induction of apoptosis. Biol Chem., 382: 1663-1668.
153. Herszényi, L, Farinati, F, Miheller, P, and, Tulassay, Z. 2008. Chemoprevention of colorectal cancer: feasibility in everyday practice?. Eur J Cancer Prev., 17: 502-514.
154. Williams, C D, Satia, J A, Adair, L S, Stevens, J, Galanko, J, Keku, T O, and, Sandler, R S. 2010. Antioxidant and DNA methylation-related nutrients and risk of distal colorectal cancer. Cancer Causes and Control, 21: 1171-1181.
155. Yeon, J Y, Suh, Y J, Kim, S W, Baik, H W, Sung, C J, Kim, H S, and, Sung, M K. 2011. Evaluation of dietary factors in relation to the biomarkers of oxidative stress and inflammation in breast cancer risk. Nutrition., 27: 912-918.
156. Yang, C S, Lu, G, Ju, J, and, Li, G X. 2010. Inhibition of inflammation and carcinogenesis in the lung and colon by tocopherols. Ann N Y Acad Sci., 1203: 29-34.
157. Kopparapu, N. 2011. Miracle nutrient. Inter J Phar and Tech, 3: 1140-1164.
158. Rath, M, and, Pauling, L. 1992. Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic lysine analogs. J Ortho Med., 7: 17-23.
159. Roomi, M W, Ivanov, V, Kalinovsky, T, Niedzwiecki, A, and, Rath, M. 2004. Synergistic effect of combination of lysine, proline, arginine, ascorbic acid and epigallocathechin gallate on colon cancer cell line HT116. J Am Nutrac Assoc., 7: 40-43.
160. Roomi, M W, Ivanov, V, Kalinovsky, T, Niedzwiecki, A, and, Rath, M. 2005. In vivo antitumor effect of ascorbic acid, lysine, praline, and green tea extract on human prostate cancer PC-3 xenographs in nude mice: evaluation of tumor growth and immunohistochemistry. In Vivo., 19: 179-184.
161. Roomi, M W, Roomi, N W, Ivanov, V, Kalinovsky, T, Niedzwiecki, A, and, Rath, M. 2005. Modulation of N-methyl-N-nitrosourea induced mammary tumors in Spargue-Dawley rats by combination of lysine, proline, arginine, ascorbic acid and green tea extract. Breast Cancer Res., 7: R291-R295.
162. Roomi, M W, Ivanov, V, Kalinovsky, T, Niedzwiecki, A, and, Rath, M. 2005. In vivo antitumor effect of ascorbic acid, lusine, praline and green tea extract on human colon cancer cell HTC 116 xenographs in nude mice. Oncol Rep., 12: 421-425.
163. Roomi, M W, Ivanov, V, Kalinovsky, T, Niedzwiecki, A, and, Rath, M. 2005. Antitumor effect of nutrient synergy on human osteosarcoma cells U2OS, MMNG-HOS, and Ewing's sarcoma SK-ES.1. Oncol Rep., 13: 253-257.
164. Harakeh, S, Abdel-Massih, R M, Gil, P R, Sperling, R A, Meinhardt, A, Niedwiecki, A, Rath, M, Parak, W J, and, Baydoun, E. 2010. The effect of PEG-coated gold nanoparticles on the anti-proliferative potential of Specific Nutrient Synergy. Nanotoxicology., 4 (2): 177-185.
165. Roomi, M W, Ivanov, V, Kalinovsky, T, and, Niedzwiecki, A. 2004. Rath M. Antitumor effect of ascorbic acid, lysine, proline, arginine and epigallocatechin gallate in prostate cancer cell lines PC3, LNCaP and DU 145. Res Commun Mol Pathol Pharmacol, 115-116: 251-264.
166. Niedzwiecki, A, Roomi, M W, Kalinovsky, T, and, Rath, M. 2010. Micronutrient synergy- a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev, 29 (3): 529-542.
167. Harakeh, S, Diab-Assaf, M, Niedzwiecki, A, Khalife, J, Abu-El-Ardat, K, and, Rath, M. 2006. Apoptosis induction by Epican Forte in HTLV-1 positive and negative malignant T-cells. Leuk Res., 30: 869-881.
168. Roomi, M W, Ivanov, V, Netke, S, Kalinovsky, T, Niedzwiecki, A, and, Rath, M. 2006. In vivo and in vitro antitumor effect of ascorbic acid, lysine, proline and green tea extract on human melanoma cell line A2058. In Vivo., 20 (1): 25-32.
169. Roomi, M W, Roomi, N W, Kalinovsky, T, Niedzwiecki, A, and, Rath, M. 2010. In vivo and in vitro effect of a nutrient mixture on human hepatocarcinoma cell line SK-HEP-1. Exp Oncol., 32 (2): 84-91.
170. Mukhtar, H, and, Ahmad, N. 1999. Cancer chemoprevention: future holds in multiple agents: Contemporary issues in Toxicology. Toxicol Appl Pharmacol., 158: 207-210.
171. Halliwell, B. 2007. Dietary polyphenols: good, bad, or indifferent for your health?. Cardiovas Res., 73: 341-347.
172. Chen, L, Lee, M J, Li, H, and, Yang, C S. 1997. Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos., 25: 1045-1050.
173. Isbrucker, R A, Edwards, J A, Wolz, E, Davidovich, A, and, Bausch, J. 2005. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem Toxicol., 44: 636-650.
174. Bonkovsky, H L. 2006. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med., 144: 68-71.
175. Galati, G, Lin, A, Sultan, A M, and, OBrien, P J. 2006. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radical Biol Med., 40: 570-580.
176. Lambert, J D, Sang, S, and, Yang, C S. 2007. Possible controversy over dietary polyphenols: benefits vs risks. Chem Res Toxicol, 20: 583-585.
177. Martin, K R, and, Appel, C L. 2010. Polyphenols as dietary supplements: a double-edged sword. Nutr Diet Suppl., 2: 1-12.
178. Weisburg, J H, Weissman, D B, Sedaghat, T, and, Babich, H. 2004. In vitro cytotoxicity of epigallocatechin gallate and tea extracts to cancerous and normal cells from the human oral cavity. Basic Clin Pharmacol Toxicol., 95: 191-200.
179. Hong, J, Lu, H, Meng, X, Ryu, J H, Hara, Y, and, Yang, C S. 2002. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res., 62: 7241-7246.
180. Gleiter, H. 2000. Nanostructured materials: basic concepts and microstructure. Acta Mater, 48: 1-29.
181. McNeil, S E. 2005. Nanotechnology for the biologist. J Leuko Biol., 78: 585-594.
182. Grodzinski, P, Silver, M, and, Molnar, L K. 2006. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn., 6 (3): 307-318.
183. Devalapally, H, Shenoy, D, Little, S, Langer, R, and, Amiji, M. 2007. Poly (ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemo Pharmacol., 59 (4): 477-484.
184. Kawasaki, E S, and, Player, A. 2005. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine, 1: 101-109.
185. Ferrari, M. 2005. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer, 5: 161-171.
186. Alexis, F, Pridgen, E, Molnar, L K, and, Farokhzad, O C. 2008. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm, 5: 505-515.
187. Jain, R K. 1987. Transport of molecules in the tumor interstitium: a review. Cancer Res, 47: 3039-3051.
188. Davis, M E, Chen, Z G, and, Shin, D M. 2008. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov., 7: 771-782.
189. Nair, H B, Sung, B, Yadav, V R, Kannappan, R, Chaturvedi, M M, and, Aggarwal, B B. 2010. Delivery of anti-inflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochem Pharmacol., 80 (12): 1833-1843.
190. Duncan, R, Vicent, M J, Greco, F, and, Nicholson, R I. 2005. Polymer-drug conjugates: towards a novel approach for the treatment of endocrine-related cancer. Endocr Relat Cancer., 12 (Suppl 1): S189-199.
191. Vaupel, P, Kallinowski, F, and, Okunieff, P. 1989. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 49: 6449-6465.
192. Schellenberger, E A, Bogdanov, A Jr., Hogemann, D, Tait, J, Weissleder, R, and, Josephson, L. 2002. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Mol Imaging. 1: 102-107.
193. Mazar, A P. 2008. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res, 14: 5649-5655.
194. Ganta, S, and, Amiji, M. 2009. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm, 6: 928-939.
195. Szoka, F Jr., and, Papahadjopoulos, D. 1978. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A, 75: 4194-4198.
196. Kim, S, and, Martin, G M. 1981. Preparation of cell-size unilamellar liposomes with high captured volume and defined size distribution. Biochim Biophys Acta, 646: 1-9.
197. Meure, L A, Foster, N R, and, Dehghani, F. 2008. Conventional and dense gas techniques for the production of liposomes: a review. AAPS PharmSciTech, 9: 798-809.
198. Siddiqui, I A, Adhami, V M, Ahmad, N, and, Mukhtar, H. 2010. Nanochemoprevention: sustained release of bioactive food components for cancer prevention. Nutr Cancer., 62 (7): 883-890.
199. Gref, R, Minamitake, Y, Peracchia, M T, Trubetskoy, V, Torchilin, V, and, Langer, R. 1994. Biodegradable long circulating polymeric nanospheres. Science., 263: 1600-1603.
200. Peer, D, Karp, J M, Hong, S, Farokhzad, O C, Margalit, R, and, Langer, R. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol., 2: 751-760.
201. Siddiqui, I A, Adhami, V M, Christopher, J, Chamcheu, and, Mukhtar, H. 2012. Impact of nanotechnology in cancer: emphasis on nanochemoprevention. Int J Nanomed., 7: 591-605.
202. Anand, P, Nair, H B, Sung, B, Kunnumakkara, AB, Yadav, VR, Tekmal, RR. 2010. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol., 79 (3): 330-338.
203. Sharma, R A, McLelland, H R, Hill, K A, Ireson, C R, Euden, S A, Manson, M M. 2001. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res, 7: 1894-1900.
204. Sharma, R A, Euden, S A, Platton, S L, Cooke, D N, Shafayat, A, Hewitt, H R. 2004. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res, 10: 6847-6854.
205. Cruz-Correa, M, Shoskes, D A, Sanchez, P, Zhao, R, Hylind, L M, Wexner, S D. 2006. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol, 4: 1035-1038.
206. Dhillon, N, Aggarwal, B B, Newman, R A, Wolff, R A, Kunnumakkara, A B, Abbruzzese, J L. 2008. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res, 14: 4491-4499.
207. Bhardwaj, A, Sethi, G, Vadhan-Raj, S, Bueso-Ramos, C, Takada, Y, Gaur, U. 2007. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 109: 2293-22302.
208. Mohanty, C, Das, M, and, Sahoo, S K. 2012. Emerging role of nanocarriers to increase the solubility and bioavailability of curcumin. Exp Opin Drug Deliv.,. doi:10.1517/17425247.2012.724676
209. Bisht, S, Feldmann, G, Soni, S, Ravi, R, Karikar, C, and, Maitra, A. 2007. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology, 5: 3
210. Sahu, A, Kasoju, N, and, Bora, U. 2008. Fluorescence study of the curcumin-casein micelle complexation and its application as a drug nanocarrier to cancer cells. Biomacromolecules, 9: 2905-2912.
211. Thangapazham, R L, Puri, A, Tele, S, Blumenthal, R, and, Maheshwari, R K. 2008. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol., 32 (5): 1119-1123.
212. Das, R K, Kasoju, N, and, Bora, U. 2010. Encapsulation of curcumin in alginatechitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine., 6 (1): 153-160.
213. Li, J, Wang, Y, Yang, C, Wang, P, Delschlager, DK, Zheng, Y. 2009. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol Pharmacol., 76 (1): 81-90.
214. Anand, P, Nair, H B, Sung, B, Kunnumakkara, AB, Yadav, VR, Tekmal, RR. 2010. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol, 79: 330-338.
215. Onoue, S, Takahashi, H, Kawabata, Y, Seto, Y, Hatanaka, J, Timmermann, B. 2010. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci., 99 (4): 1871-1881.
216. Sou, K, Oyajobi, B, Goins, B, Phillips, W T, and, Tsuchida, E. 2009. Characterization and cytotoxicity of self-organized assemblies of curcumin and amphipathic poly(ethylene glycol). J Biomed Nanotechnol., 5 (2): 202-208.
217. Yallapu, M M, Gupta, B K, Jaggi, M, and, Chauhan, S C. 2010. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci., 351 (1): 19-29.
218. Shaikh, J, Ankola, D D, Beniwal, V, Singh, D, and, Ravi Kumar, M NV. 2009. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci., 37: 223-230.
219. Zhou, X J, Hu, X M, Yi, Y M, and, Wan, J. 2009. Preparation and body distribution of freeze-dried powder of ursolic acid phospholipid nanoparticles. Drug Dev Ind Pharm, 35: 305-310.
220. Barras, A, Mezzetti, A, Richard, A, Lazzaroni, S, Roux, S, Melnyk, P. 2009. Formulation and characterization of polyphenol-loaded lipid nanocapsules. Int J Pharm, 379: 270-277.
221. Barik, A, Priyadarsini, K I, and, Mohan, H. 2003. Photophysical studies on binding of curcumin to bovine serum albumins. Photochem Photobiol, 77: 597-603.
222. Shutava, T G, Balkundi, S S, Vangala, P, Steffan, J J, Bigelow, R L, Cardelli, J A, ONeal, D P, and, Lvov, Y M. 2009. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano, 3 (7): 1877-1885.
223. Italia, J L, Datta, P, Ankola, D D, and, Kumar, MNVR. 2008. Nanoparticles enhance per oral bioavailability of poorly available molecules: epigallocatechin gallate nanoparticles ameliorates cyclosporine induced nephrotoxicity in rats at three times lower dose than oral solution. J Biomed Nanotechnol, 4: 304-312.
224. Siddiqui, I A, Adhami, V M, Bharali, D J, Hafeez, BB, Asim, M, Khwaja, SI. 2009. Introducing nanochemo-prevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3- gallate. Cancer Res, 69: 1712-1716.
225. Hu, B, Ting, Y, Yang, X, Tang, W, Zeng, X, and, Huang, Q. 2012. Nanochemoprevention by encapsulation of (-)-epigallocatechin-3-gallate with bioactive peptides/chitosan nanoparticles for enhancement of its bioavailability. Chem Commun., 48: 2421-2423.
226. Rocha, S, Generalov, R, Pereira Mdo, C, Peres, I, Juzenas, P, and, Coelho, M A. 2011. Epigallocatechin gallate-loaded polysaccharide nanoparticles for prostate cancer chemoprevention. Nanomedicine (Lond), 6 (1): 79-87.
227. Singh, M, Bhatnagar, P, Srivastava, A K, Kumar, P, Shukla, Y, and, Gupta, K C. 2011. Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles. J Biomed Nanotechnol., 7 (1): 202
228. Narayanan, N K, Nargi, D, Randolph, C, and, Narayanan, B A. 2009. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer., 125 (1): 1-8.
229. Teskac, K, and, Kristl, J. 2010. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm., 390 (1): 61-69.
230. Wang, D, Taylor, E W, Wang, Y, Wan, X, and, Zhang, J. 2012. Encapsulated nanoepigallocatechin-3-gallate and elemental selenium nanoparticles as paradigms for nanochemoprevention. Int J Nanomedicine, 7: 1711-1721.
231. Hsieh, D S, Wang, H, Tan, S W, Huang, YH, Tsai, CY, Yeh, MK. 2011. The treatment of bladder cancer in a mouse model by epigallocatechin-3-gallate-gold nanoparticles. Biomaterials., 32 (30): 7633-7640.
232. Jeong, S Y, Park, S J, Yoon, S M, Jung, J, Woo, H N, Yi, S L. 2009. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization. J Control Release, 139: 239-245.
233. Blanco, E, Bey, E A, Dong, Y, Weinberg, B D, Sutton, D M, Boothman, D A. 2007. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release, 122: 365-374.
234. Mukerjee, A, and, Vishwanatha, J K. 2009. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res, 29: 3867-3875.
235. Gupta, V, Aseh, A, Rios, C N, Aggarwal, B B, and, Mathur, A B. 2009. Fabrication and characterization of silk fibroin-derived curcumin nanoparticles for cancer therapy. Int J Nanomedicine, 4: 115-122.
236. Zu, Y G, Yuan, S, Zhao, X H, Zhang, Y, Zhang, X N, and, Jiang, R. 2009. Preparation, activity and targeting ability evaluation in vitro on folate mediated epigallocatechin-3-gallate albumin nanoparticles. Yao Xue Xue Bao, 44: 525-531.